A Randomized Controlled Trial of Panretinal Photocoagulation With and Without Intravitreal Ranibizumab in Treatment-Naive Eyes With Non–high-Risk Proliferative Diabetic Retinopathy

Abstract

Intravitreal ranibizumab in combination with PRP can be an effective treatment in eyes with non-high-risk proliferative diabetic retinopathy and diabetic macular edema.

Panretinal Photocoagulation vs. Panretinal Photocoagulation Plus Intravitreal Ranibizumab in High-Risk Proliferative Diabetic Retinopathy

“…The results of the current study are consistent with data from other studies [8][9][10][11][12] regarding the absence of any apparent association between intravitreal ranibizumab injection and increased IOP, cataract development or progression or increased rates of endophthalmitis related to the study drug.…”

“…In our study group, patients had a mean age of presentation in PRP group is 61 years in PRP group and 58 years in PRP plus group, which was comparable to the mean age in the study by Filho et al⁸ (63.3 years in PRP group and 50.5 in PRP plus group), Panshi et al⁹ (66.3 years), Josef et al 10 (65 years in PRP group and 64 years in PRP plus group), Fequira et al 11 (60 years in PRP group and 62 years in PRP plus group) and Daniel et al 12 (56 years in PRP group and 59 years in PRP plus group). Most of our patients were males (21, 58.33%), which is similar in other studies.…”

Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial

“…There is only another study [17] that has assessed IVR efficacy for high-risk PDR in a clinical trial setting. The authors included two treatment arms in their trial: PRP alone and PRP + IVR.…”

“…Scarce data is available for ranibizumab, an approved agent for intravitreal use, with activity against all isoforms of VEGF and widely administered throughout the world [1]. To our knowledge, there are only 2 published randomized studies in this field, one focusing on non-high-risk [16] and the other on high-risk [17] PDR eyes. In this last trial [17], a control group was assigned to PRP and the study group received 2 sessions of PRP plus a single intravitreal ranibizumab (IVR) injection.…”

“…To our knowledge, there are only 2 published randomized studies in this field, one focusing on non-high-risk [16] and the other on high-risk [17] PDR eyes. In this last trial [17], a control group was assigned to PRP and the study group received 2 sessions of PRP plus a single intravitreal ranibizumab (IVR) injection. Retreatment was performed with IVR in monotherapy.…”